Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins

Arthritis and Rheumatism

Volumn 52, Issue 11, 2005, Pages 3433-3438

  Huizinga, Tom W J ^a   Amos, Christopher I ^b   Van Der Helm Van Mil, Annette H M ^a   Chen, Wei ^b   Van Gaalen, Floris A ^a   Jawaheer, Damini ^c   Schreuder, Geziena M T ^a   Wener, Mark ^d   Breedveld, Ferdinand C ^a   Ahmad, Naila ^d   Lum, Raymond F ^e   De Vries, Rene R P ^a   Gregersen, Peter K ^f   Toes, Rene E M ^a   Criswell, Lindsey A ^e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CITRULLINATED PROTEIN ANTIBODY; CITRULLINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; HLA DR ANTIGEN; PROTEIN; UNCLASSIFIED DRUG;

ALLELE; AMERICAN COLLEGE OF RHEUMATOLOGY CLASSIFICATION; ANTIGEN SPECIFICITY; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE PERSISTENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; HUMAN; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; NORTH AMERICA; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIBLING;

ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; EPITOPES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HLA-DR ANTIGENS; HUMANS; JOINTS; NETHERLANDS; ODDS RATIO; PEPTIDES, CYCLIC; PHENOTYPE; RISK FACTORS; UNITED STATES;

EID: 27744550413     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21385     Document Type: Article

References (19)

1. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30-7.
2. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13.
3. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
4. Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
5. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
6. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
7. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.
8. Van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004;50:2113-21.
9. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van 't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recentonset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
10. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171:538-41.
11. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.
12. Aken J, Bilsen JA, Allaart CF, Huizinga TW, Breedveid FC. The Leiden Early Arthritis Clinic. Clin Exp Rheumatol 2003;21 Suppl 31:5100-5.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743-5.
15. Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Etzel C, et al, for the North American Rheumatoid Arthritis Consortium. Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum 2003;48:906-16.
16. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin: rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 2002;30:97-101.
17. Van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoanti-body tests for rheumatoid arthritis. Ann Rheum Dis 2005;64:1510-2.
18. German JD, David-Vaudey E, Pai M, Lum RF, Criswell LA. Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis Rheum 2004;50:3476-84.
19. Ferucci ED, Majka DS, Parrish LA, Moroldo MB, Ryan M, Passo M, et al. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticularonset juvenile rheumatoid arthritis. Arthritis Rheum 2005;52:239-46.